Purpose: To develop antimetabolite-based consolidation regimens that minimize acute and long-term toxicities and improve the survival rate of children with standard-risk B-lineage acute lymphocytic leukemia (ALL).
Patients And Methods: Seven hundred twenty-seven eligible patients with standard-risk early pre-B ALL were registered onto the study. Seven hundred sixteen patients attained a complete remission (CR) after induction therapy. Of these, 114 patients were randomized to a different regimen and were the subject of a separate report. Six hundred two patients were randomized to receive one the following regimens: intermediate-dose methotrexate (IDMTX) with leucovorin rescue on weeks 7, 10, 13, 16, 19, and 22 (regimen A); regimen A plus asparaginase (ASP) administered intramuscularly (i.m.) weekly for 24 weeks (regimen B); or regimen A plus a 24-hour infusion of cytarabine (AraC) with each IDMTX (regimen C). After consolidation, patients were placed on maintenance therapy through week 156. Regimens A and C were opened in February 1986, and regimen B in May 1987. Comparisons are based on concurrently randomized patients (May 1987 to January 1991 between regimens A and B, and February 1986 to January 1991 between regimens A and C).
Results: The 5-year continuous CR (CCR) rates were not significantly different: A versus B, 78.1% (3.9 +/- SE) versus 83.3% +/- 3.5% and A versus C, 79.4% +/- 3.2% versus 83.5% +/- 2.9%; P by one-sided log-rank tests were .27 and .34, respectively. Significant treatment differences were not found with regard to sex, rate of testicular and CNS relapse, or CNS complications. During consolidation, regimen C had significantly more bacterial infections (P = .0032) and days spent in the hospital (P < .001) compared with regimen A.
Conclusion: We were unable to show a statistical advantage of adding either ASP or AraC to IDMTX in terms of improvement in event-free survival (EFS).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.1998.16.8.2840 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing stroke-induced abnormal muscle coactivation in the upper limb using the surface EMG co-contraction Index: A systematic review.
J Electromyogr Kinesiol
January 2025
Department of Rehabilitation Sciences, the Hong Kong Polytechnic University, Hong Kong Special Administrative Region of China. Electronic address:
Electromyography (EMG) is increasingly used in stroke assessment research, with studies showing that EMG co-contraction (EMG-CC) of upper limb muscles can differentiate stroke patients from healthy individuals and correlates with clinical scales assessing motor function. This suggests that EMG-CC has potential for both assessing motor impairments and monitoring recovery in stroke patients. However, systematic reviews on EMG-CC's effectiveness in stroke assessment are lacking.
View Article and Find Full Text PDFLipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies.
ACS Nano
January 2025
Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Antidrug antibodies (ADAs) against biologics present a major challenge for sustained biotherapy, including enzyme replacement therapies and adeno-associated virus (AAV) gene therapies. These antibodies arise from undesirable immune responses, leading to altered pharmacokinetics, reduced efficacy, and adverse reactions. In this study, we introduced a rationally designed lipid-rapamycin (Rapa)-based nanovaccine to restore immune tolerance to biologics and overcome drug resistance.
View Article and Find Full Text PDFProgrammable Porous Silicon Microparticles for Temporally Staged Drug Delivery in Combination Cancer Immunotherapy.
ACS Appl Mater Interfaces
January 2025
Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea.
Combination therapies using checkpoint inhibitors with immunostimulatory agonists have attracted great attention due to their synergistic therapeutic effects for cancer treatment. However, such combination immunotherapies require specific timing of doses to show sufficient antitumor efficacy. Sequential treatment usually requires multiple administrations of the individual drugs at specific time points, thus increasing the complexity of the drug regimen and compromising patient compliance.
View Article and Find Full Text PDFGadopiclenol Enables Reduced Gadolinium Dose While Maintaining Quality of Pulmonary Arterial Enhancement for Pulmonary MRA: An Opportunity for Improved Safety and Sustainability.
Invest Radiol
January 2025
From the Departments of Radiology (J.F.H., S.Y.C., J.-P.G., J.S., P.N., S.B.R., T.M.G.), Biomedical Engineering (S.B.R., T.M.G.), Medical Physics (S.Y.C., S.B.R., T.M.G.), Medicine (S.B.R.), and Emergency Medicine (S.B.R.), University of Wisconsin-Madison, WI; and Department of Diagnostic and Interventional Radiology (J.F.H., J.-P.G.), University Hospital Würzburg, Würzburg, Germany.
Rationale And Objectives: Pulmonary magnetic resonance angiography (MRA) is an imaging method with proven utility for the exclusion of pulmonary embolism and avoids the need for ionizing radiation and iodinated contrast agents. High-relaxivity gadolinium-based contrast agents (GBCAs), such as gadopiclenol, can be used to reduce the required gadolinium dose for pulmonary MRA. The aim of this study was to compare the contrast enhancement performance of gadopiclenol with an established gadobenate dimeglumine-enhanced pulmonary MRA protocol.
View Article and Find Full Text PDFAssessing the "Reach" of a Fire-Based Mobile Integrated Health Buprenorphine Induction Program through an Implementation Science Lens.
Prehosp Emerg Care
January 2025
Medical College of Wisconsin, Department of Emergency Medicine.
Objectives: Medication for opioid use disorder (MOUD) reduces morbidity and mortality for patients with opioid use disorder (OUD). Recent administrative and legislative changes have made MOUD possible in the prehospital setting. We use an implementation science framework to outline the Reach of a fire department EMS-based Mobile Integrated Health (MIH) prehospital MOUD program.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!